Next Article in Journal
Two New Diketomorpholine Derivatives and a New Highly Conjugated Ergostane-Type Steroid from the Marine Algal-Derived Endophytic Fungus Aspergillus alabamensis EN-547
Previous Article in Journal
Cloning, Synthesis and Functional Characterization of a Novel α-Conotoxin Lt1.3
Previous Article in Special Issue
Bioactive Peptides from Cartilage Protein Hydrolysate of Spotless Smoothhound and Their Antioxidant Activity In Vitro
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Mar. Drugs 2018, 16(4), 113; https://doi.org/10.3390/md16040113

Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization

1
CONACYT-Medical and Pharmaceutical Biotechnology, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), Guadalajara, Jalisco, C.P. 44270, Mexico
2
Biomedical Innovation Department, Centro de Investigación Científica y Educación Superior de Ensenada, (CICESE), Ensenada, Baja California, C.P. 22860, Mexico
3
Research and Development Department, Laboratorios Silanes S.A. de C.V., Ciudad de México, C. P. 03100, Mexico
4
Research and Development Department, Teraclón IDF S.L., Calle de Santiago Grisolía, Tres Cantos, 28020 Madrid, Spain
*
Author to whom correspondence should be addressed.
Received: 12 December 2017 / Revised: 22 February 2018 / Accepted: 26 March 2018 / Published: 31 March 2018
(This article belongs to the Special Issue The Pharmacological Potential of Marine-Derived Peptides and Proteins)
View Full-Text   |   Download PDF [14065 KB, uploaded 31 March 2018]   |  

Abstract

Variable new antigen receptor domain (vNAR) antibodies are novel, naturally occurring antibodies that can be isolated from naïve, immune or synthetic shark libraries. These molecules are very interesting to the biotechnology and pharmaceutical industries because of their unique characteristics related to size and tissue penetrability. There have been some approved anti-angiogenic therapies for ophthalmic conditions, not related to vNAR. This includes biologics and chimeric proteins that neutralize vascular endothelial growth factor (VEGF)165, which are injected intravitreal, causing discomfort and increasing the possibility of infection. In this paper, we present a vNAR antibody against human recombinant VEGF165 (rhVEGF165) that was isolated from an immunized Heterodontus francisci shark. A vNAR called V13, neutralizes VEGF165 cytokine starting at 75 μg/mL in an in vitro assay based on co-culture of normal human dermal fibroblasts (NHDFs) and green fluorescence protein (GFP)-labeled human umbilical vein endothelial cells (HUVECs) cells. In the oxygen-induced retinopathy model in C57BL/6:Hsd mice, we demonstrate an endothelial cell count decrease. Further, we demonstrate the intraocular penetration after topical administration of 0.1 μg/mL of vNAR V13 by its detection in aqueous humor in New Zealand rabbits with healthy eyes after 3 h of application. These findings demonstrate the potential of topical application of vNAR V13 as a possible new drug candidate for vascular eye diseases. View Full-Text
Keywords: vNAR; single chain binding domain; VEGF165; intraocular penetration; Heterodontus fransisci; horn shark; age-related macular degeneration; diabetic retinopathy vNAR; single chain binding domain; VEGF165; intraocular penetration; Heterodontus fransisci; horn shark; age-related macular degeneration; diabetic retinopathy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Share & Cite This Article

MDPI and ACS Style

Camacho-Villegas, T.A.; Mata-González, M.T.; García-Ubbelohd, W.; Núñez-García, L.; Elosua, C.; Paniagua-Solis, J.F.; Licea-Navarro, A.F. Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization. Mar. Drugs 2018, 16, 113.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top